Reports of anti-cartilage antibody in human sera are uncommon and have been limited to a few cases of relapsing polychondritis (Hughes et al., 1972; Rogers et al., 1973) .
In the course of a survey of anti-tissue antibodies by immunofluorescence on rat tissues we found a serum which reacted strongly with a piece of tracheal cartilage accidentally included in one of the blocks. Since this occurrence in 1975, tracheal and costal cartilage have been included routinely in the tissue blocks, and we have found more than 40 patients with anti-cartilage antibody, most of whom had rheumatoid arthritis. This paper describes the antibody, its probable identity with anti-type II collagen, and its incidence among 5000 patients and blood donors.
Material and methods

SOURCES OF SERA
I Blood donors 1825 sera were kindly supplied by the Oxford BTS, who also provided details of the age and sex (but not the names) of donors. 2 Patients of the National Spinal Injuries Centre Inpatients were tested once a month and outpatients at each six-monthly attendance. 1314 patients were tested on an average of 2-3 occasions.
Received for publication 23 Fluorescein-conjugated sheep anti-human sera: anti-immunoglobulin, anti-IgG, anti-IgM, anti-IgA and anti-C3 were obtained from Wellcome Reagents Ltd. Sera to be tested were screened at a dilution of 1:10 using the anti-immunoglobulin. The immunoglobulin class of any antibody present was then determined and titrated with the specific immunoglobulin antisera.
SHEEP CELL AGGLUTINATION TEST (SCAT)
Sera to be tested were diluted in 2-5 % sheep serum (Greenbury, 1960 Anti-cartilage antibody was found in 40 patients, all but two of whom had rheumatoid arthritis or psoriatic arthropathy, an incidence of about 3 % (see Table  1 ). The two non-rheumatoid patients with anticartilage antibody were from among 1314 paraplegics; they gave only weak but repeated positive reactions. In addition, there were 21 doubtful positives, that is, patients from whom a single serum, either one of a series or the only serum tested, gave a weak anti-cartilage reaction. At least 14 of these patients were suffering from rheumatoid arthritis or psoriatic arthropathy. No cartilage positive serum was found among blood donors or patients with locomotor disease other than rheumatoid arthritis, including 284 patients with osteoarthritis. The 40 patients with anti-cartilage antibody are detailed in Table 2 . The only finding positively correlated with anti-cartilage antibody was the presence of articular erosions (x-ray grades 3 and 4), which were. or had been, present in 25 (78 %) of the 32 patients on whom data were available. The actual incidence of erosions probably exceeded 78 %, since the current practice is, after initial x-rays of hands and feet, to take no further radiographs except perhaps at three-year intervals, unless surgical intervention is contemplated. Table 2 were seropositive, that is, they have had positive tests for rheumatoid factor at some stage in their disease. Three of the four seronegative patients had rheumatoid arthritis of only short duration, and, statistically speaking, at least one of them is likely to become seropositive. This would result in an overall seropositivity rate of 92% for anti-cartilage positive patients, which contrasts with an overall rate of 82% for the 960 patients with rheumatoid arthritis whose serology we have followed for at least three years (unpublished data).
Most patients in Table 2 were tested for tissue antibodies on a number of occasions. In the majority, anti-cartilage antibody was present at the first test and persisted throughout the period of surveillance. In some the antibody appeared for the first time while the patient was under observation, and in others the antibody initially present disappeared; both groups of patients tended to be those whose disease was of shorter duration. In no case was it possible to link the appearance of the antibody with any clinical event.
SPECIFICITY OF ANTI-CARTILAGE ANTIBODY
Since no antibody to any other tissue present in the blocksregularlyaccompanied anti-cartilage antibody, it seemed probable that the latter owed its specificity to some constituent peculiar to cartilage-either proteoglycan or type II collagen (Miller, 1973 As virtually all our anti-cartilage sera were from cases of rheumatoid arthritis, 100 random anticartilage negative RA sera were tested by HA as controls. Among these 100 sera there were only five weak positives with titres from 1:2 to 1:10. These were retested by immunofluorescence for anticartilage antibody; the two strongest (HA titre 1:10) were found to be IF positive at a titre of 1:5 (that is, below the dilution at which sera were originally screened).
Discussion
Our findings seem to be of some interest because they concern an autoantibody to a tissue directly involved in a disease generally thought to be of autoimmune origin. The antibody hitherto regarded as rare is certainly very limited in its distribution and is practically confined to patients with rheumatoid arthritis.
The evidence points strongly to the anti-cartilage antibody here described being closely related to, if not identical with, antibody to native type H collagen, the distribution of which in the body is almost entirely confined to cartilage and intervertebral disc Muir, 1975, 1976; Miller, 1973) . However, the two antibodies are not identical in every case, since two of the patients with anti-cartilage antibody had negative HA tests for anti-collagen type II; moreover, the titres of anti-cartilage correlate only roughly with those of anti-collagen type II. There is thus some heterogeneity within the anti-cartilage sera, possibly in the specificity for different antigenic sites on the collagen molecule; there are also variations in patterns of fluorescence with tracheal cartilage. These heterogeneities and the more detailed specificities of the antibodies are being further investigated.
There have been a number of reports of anti-collagen antibodies in rheumatoid arthritis.These mostly concern native or denatured type I collagen: in serum (Adam et al., 1977; Michaeli and Fudenberg, 1974) ; in synovial fluids (Cracchiolo et al., 1975; Menzel et al., 1976) ; or antigen-antibody complexes in synovial fluid cells (Steffen et al., 1974) . One group of workers, however, have found antibody to type II collagen in synovial fluids (Mestecky and Miller, 1975) and in serum in both the IgG and IgM fractions (Andriopoulos et al., 1976a, b, c (Steffen, 1970) . Indeed, it has been shown experimentally that immunisation with type II collagen can produce arthritis in rats (Trentham et al., 1977) . We can offer no evidence on this topic, but the low incidence of anti-cartilage antibody suggests that it is unlikely to be a prime aetiological factor. No doubt anti-cartilage antibody is present at some time in the disease more often than we have found it here, since we have seen it sometimes to be only fleetingly present, or to disappear after being well established; even so, our results suggest that it is unlikely to occur at all in more than a small minority of patients. This argument against a causative role for anti-cartilage antibody would have less force if the serum antibody were, as very well may be the case, only an 'overflow' of that produced in the synovial tissues. We have not found anticartilage antibody in the few rheumatoid synovial fluids examined, but the fluids were not pre-treated with collagenase or hyaluronidase. The high correlation of anti-cartilage antibody with erosions is no better evidence for it being a cause rather than a consequence of cartilage damage. It is nonetheless interesting to speculate why antibody to cartilage is not found in osteoarthritis which involves extensive damage to cartilage.
The figures are too small for any statistical comment on psoriatic arthropathy, but it is worth noting that the single patient with anti-cartilage antibody and psoriasis was seropositive and therefore may more properly belong in the group in which rheumatoid arthritis and psoriasis are coincidental.
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